

## Message Text

UNCLASSIFIED

PAGE 01 STATE 123012  
ORIGIN HEW-06

INFO OCT-01 EUR-12 ISO-00 OES-07 /026 R

DRAFTED BY DHEW:FDA: JRWEINROTH, M.D.:PFF  
APPROVED BY OES/APT/BMP: WJWALSH, III  
EUR/NE:JPSHUMATE(INFO)  
DHEW/OIH:RFISCHER

-----281849Z 111314 /42

R 271524Z MAY 77  
FM SECSTATE WASHDC  
TO AMEMBASSY LONDON

UNCLAS STATE 123012

E.O. 11652: N/A

TAGS: OTRA, OCON, TBIO, UK

SUBJECT: FDA REPRESENTATIVE ATTENDING INTERNATIONAL  
CONFERENCE

FDA ADVISES THAT GEORGE L. WOLFF, PH.D., CHIEF, DIVISION  
OF MUTAGENESIS RESEARCH, NATIONAL CENTER FOR TOXICOLOGICAL  
RESEARCH, WILL BE IN EDINBURGH, SCOTLAND, JULY 7-15, 1977,  
DURING WHICH TIME HE WILL ATTEND THE SECOND INTERNATIONAL  
MUTAGEN CONFERENCE AND WILL CO-CHAIR ONE OF THE SCIENTIFIC  
SESSIONS. DR. WOLFF WILL BE ON ANNUAL LEAVE IN ENGLAND  
JULY 18-29, 1977.

ASSISTANCE OF EMBASSY WILL NOT BE REQUIRED. VANCE

UNCLASSIFIED

NNN

## Message Attributes

**Automatic Decaptioning:** X  
**Capture Date:** 01-Jan-1994 12:00:00 am  
**Channel Indicators:** n/a  
**Current Classification:** UNCLASSIFIED  
**Concepts:** ITINERARY, SCIENTIFIC MEETINGS  
**Control Number:** n/a  
**Copy:** SINGLE  
**Sent Date:** 27-May-1977 12:00:00 am  
**Decaption Date:** 01-Jan-1960 12:00:00 am  
**Decaption Note:**  
**Disposition Action:** n/a  
**Disposition Approved on Date:**  
**Disposition Case Number:** n/a  
**Disposition Comment:**  
**Disposition Date:** 01-Jan-1960 12:00:00 am  
**Disposition Event:**  
**Disposition History:** n/a  
**Disposition Reason:**  
**Disposition Remarks:**  
**Document Number:** 1977STATE123012  
**Document Source:** CORE  
**Document Unique ID:** 00  
**Drafter:** FDA: JRWEINROTH, M.D.:PFF  
**Enclosure:** n/a  
**Executive Order:** N/A  
**Errors:** N/A  
**Expiration:**  
**Film Number:** D770192-0037  
**Format:** TEL  
**From:** STATE  
**Handling Restrictions:** n/a  
**Image Path:**  
**ISecure:** 1  
**Legacy Key:** link1977/newtext/t1977058/aaaaagut.tel  
**Line Count:** 43  
**Litigation Code IDs:**  
**Litigation Codes:**  
**Litigation History:**  
**Locator:** TEXT ON-LINE, ON MICROFILM  
**Message ID:** 0f874698-c288-dd11-92da-001cc4696bcc  
**Office:** ORIGIN HEW  
**Original Classification:** UNCLASSIFIED  
**Original Handling Restrictions:** n/a  
**Original Previous Classification:** n/a  
**Original Previous Handling Restrictions:** n/a  
**Page Count:** 1  
**Previous Channel Indicators:** n/a  
**Previous Classification:** n/a  
**Previous Handling Restrictions:** n/a  
**Reference:** n/a  
**Retention:** 0  
**Review Action:** RELEASED, APPROVED  
**Review Content Flags:**  
**Review Date:** 11-Feb-2005 12:00:00 am  
**Review Event:**  
**Review Exemptions:** n/a  
**Review Media Identifier:**  
**Review Release Date:** n/a  
**Review Release Event:** n/a  
**Review Transfer Date:**  
**Review Withdrawn Fields:** n/a  
**SAS ID:** 2601047  
**Secure:** OPEN  
**Status:** NATIVE  
**Subject:** FDA REPRESENTATIVE ATTENDING INTERNATIONAL CONFERENCE FDA ADVISES THAT GEORGE L. WOLFF, PH.D., CHIEF, DI  
**TAGS:** OTRA, OCON, TBIO, UK, FDA, (WOLFF, GEORGE L)  
**To:** LONDON  
**Type:** TE  
**vdkgvwkey:** odb://SAS/SAS.dbo.SAS\_Docs/0f874698-c288-dd11-92da-001cc4696bcc  
**Review Markings:**  
Margaret P. Grafeld  
Declassified/Released  
US Department of State  
EO Systematic Review  
22 May 2009  
**Markings:** Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009